Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684443 | 1.00 | NOS1 (0.39) | NOS1HTTPTK2DYRK1A | |
| SCHEMBL24553744 | 0.79 | HTT (0.44) | NOS1HTTPTK2 | |
| SCHEMBL4830696 | 0.79 | NOS1 (0.37) | NOS1HTTPTK2 | |
| SCHEMBL29863669 | 0.79 | NOS1 (0.37) | NOS1HTTPTK2 | |
| SCHEMBL4838398 | 0.79 | NOS1 (0.37) | NOS1HTTPTK2 | |
| SCHEMBL4106173 | 0.79 | DPP4 (0.43) | NOS1HTTPTK2 | |
| SCHEMBL29864632 | 0.75 | NOS1 (0.34) | NOS1HTTPTK2 | |
| SCHEMBL30774307 | 0.75 | HTT (0.36) | NOS1HTTPTK2 | |
| SCHEMBL22119097 | 0.75 | HTT (0.36) | NOS1HTTPTK2 | |
| SCHEMBL30097193 | 0.72 | HTT (0.49) | NOS1HTTDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092053-A1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4712964-A1 | COMPOUNDS AND FORMULATIONS USEFUL AS VACCINE ADJUVANTS | Merck Sharp & Dohme LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| EP-4681774-A2 | KHK INHIBITORS | Gilead Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4313967-B1 | KHK INHIBITORS | GILEAD SCIENCES INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12410160-B2 | KHK inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-08-26 | — | — | US | disclosed |
| US-20250255948-A1 | PNEUMOCOCCAL CONJUGATE VACCINES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-08-14 | — | — | US | disclosed |
| US-20240390471-A1 | COMPOUNDS AND ADJUVANT FORMULATIONS USEFUL IN PNEUMOCOCCAL VACCINES | MERCK SHARP & DOHME LLC (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024238735-A1 | COMPOUNDS AND FORMULATIONS USEFUL AS VACCINE ADJUVANTS | MERCK SHARP & DOHME LLC (US) | 2024-11-21 | — | — | WO | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-05 | — | — | US | disclosed |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230079863-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | RIBON THERAPEUTICS, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022212194-A1 | KHK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022174184-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | TANGO THERAPEUTICS, INC. (US) | 2022-08-18 | — | — | WO | disclosed |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390471-A1 | COMPOUNDS AND ADJUVANT FORMULATIONS USEFUL IN PNEUMOCOCCAL VACCINES | PHOSPHO1, NAPEPLD, PLA2G2E | NOS1 1325/4885HTT 2899/4885PTK2 1588/4885 |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | DPYD, TYMP, TK1 | NOS1 3536/4885HTT 3465/4885PTK2 2329/4885 |
| US-20210032251-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | NOS1 4862/4885HTT 3637/4885PTK2 2198/4885 |
| US-12398146-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | NOS1 4862/4885HTT 3637/4885PTK2 2198/4885 |
| US-20250255948-A1 | PNEUMOCOCCAL CONJUGATE VACCINES AND METHODS OF USE THEREOF | CD14, CD44, SPAG5 | NOS1 2956/4885HTT 2503/4885PTK2 1818/4885 |
| US-20230312586-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, PARP12, ENTPD2 | NOS1 4862/4885HTT 3637/4885PTK2 2198/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | NOS1 4160/4885HTT 4174/4885PTK2 2856/4885 |
| US-11535621-B2 | Heterobicyclic amides as inhibitors of CD38 | CD38, PARP12, ENTPD2 | NOS1 4862/4885HTT 3637/4885PTK2 2198/4885 |
| US-20260092053-A1 | KHK INHIBITORS | KHK, SLC5A2, HK1 | NOS1 1762/4885HTT 2909/4885PTK2 761/4885 |
| US-20230079863-A1 | KHK INHIBITORS | KHK, KHDRBS1, NADK | NOS1 3707/4885HTT 2855/4885PTK2 951/4885 |
| US-12410160-B2 | KHK inhibitors | KHK, KHDRBS1, NADK | NOS1 3707/4885HTT 2855/4885PTK2 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.